Doxorubicin (DX) is one of the most widely used antineoplastic drugs because it exhibits considerable activity against a broad spectrum of solid tumours and leukaemias. Unfortunately, as for anticancer drugs in general, tumours often are either resistant from the outset or become so after chemotherapy. This phenomenon, together with metastatic spread, represents the most important obstacles which limit the success of chemotherapy. In order to understand the mechanisms involved in anthracycline resistance, several experimental systems have been developed both in vitro and in vivo (Biedler et al., 1983; Dan0, 1972; Inaba et al., 1979) . Most of the in vivo studies, however, have been performed either on leukaemias or sarcomas grown in ascitic form and treated with i.p. administration of the drugs to be tested, i.e. by an assay which mimics the in vitro situation (Biedler et al., 1983; Seeber et al., 1982) , or on solid tumours whose sensitivity and resistance to DX were tested only in in vitro assays (Giavazzi et al., 1983 
Summary A doxorubicin-resistant line of B16 melanoma (B16VDXR) was obtained in vitro by continuous exposure to increasing concentrations of doxorubicin of an in vitro line (B16V) derived from the in vivo transplanted B16 melanoma. When injected s.c. into mice, B16VDXR exhibited histological features, metastatic behaviour, doubling time and tumourigenic potential similar to those of the parental B16V line. Tumours obtained by implantation of B 1 6VDXR, however, had longer latency and permitted a longer survival time than B16V and had, as in vitro, a higher DNA content. After i.v. inoculation, B16VDXR cells had lower lung colonizing capability compared to B16V. B16V and B16VDXR had significantly lower metastatic potential compared to the B 16 melanoma from which they derived. Doxorubicin treatment significantly delayed the growth of B16 and B16V transplanted s.c. and increased the life span of animals bearing B16V. B16VDXR was resistant to doxorubicin treatment when the in vitro resistance index was > 100. While the doxorubicin-resistance phenotype was stable in vitro for 50 passages, in vivo the resistance phenotype was lost in 5 passages and tumours grown from s.c. inocula of mixtures of similar percentages of sensitive and resistant cells behaved as sensitive tumours. Cis-diamminedichloroplatinum (II), although marginally active in animals bearing B16V, was highly effective in B16VDXR bearing animals, suggesting a collateral cis-diam*iinedichloroplatinum (II) sensitivity of the B16VDXR line. After a single i.v. administration, doxorubicin reached initially, in the B16VDXR line, levels similar to those found in the B16 and B16V lines, but its release was faster from the resistant line in comparison with the sensitive ones. Doxorubicin-resistance was not overcome by more frequent treatments with doxorubicin. This doxorubicinresistant tumour line obtained in vitro and used as a first in vivo transplant, may be a suitable metastatizing model for in vivo study of the mechanisms of resistance and of collateral sensitivity and for screening new drugs. Doxorubicin (DX) is one of the most widely used antineoplastic drugs because it exhibits considerable activity against a broad spectrum of solid tumours and leukaemias. Unfortunately, as for anticancer drugs in general, tumours often are either resistant from the outset or become so after chemotherapy. This phenomenon, together with metastatic spread, represents the most important obstacles which limit the success of chemotherapy. In order to understand the mechanisms involved in anthracycline resistance, several experimental systems have been developed both in vitro and in vivo (Biedler et al., 1983; Dan0, 1972; Inaba et al., 1979) . Most of the in vivo studies, however, have been performed either on leukaemias or sarcomas grown in ascitic form and treated with i.p. administration of the drugs to be tested, i.e. by an assay which mimics the in vitro situation (Biedler et al., 1983; Seeber et al., 1982) , or on solid tumours whose sensitivity and resistance to DX were tested only in in vitro assays (Giavazzi et al., 1983 (Geran et al., 1972) . Detailed description of the in vitro lines is reported in a previous paper (Supino et al., 1986) . The schematic representation of the obtained lines is given in Figure 1 . 
Index of resistance (RI) in vitro
Detailed description of the in vitro assays of levels of resistance has been reported (Supino et al., 1986) . Briefly, cells were treated at cell seeding with different concentrations of DX. After 72 h, cells were harvested by trypsinization and counted in a model ZBI Kontron Coulter Counter. The RI was evaluated as the ratio between the graphically determined concentration causing a 50% decrease in cell number at this time point (ID50) on the B16VDXR cells and the ID50 on the B16V cells.
In vivo studies All the in vivo studies were performed in B6D2F1 mice, since chemosensitivity studies on B16 melanoma were performed in this strain according to standard, accepted procedures (Geran et al., 1972) For colonization potential assay, cells harvested from tissue culture, as previously described, were injected i.v. in a 0.2 ml volume in a lateral tail vein of B6D2F1 mice. Viable tumour cells were also mixed with 106 irradiated (10OGy) cells in order to obtain more reproducible and meaningful results for quantitative analysis of experimental metastatic capacity and heparin was also added to reduce intravascular cell clumping (Stackpole et al., 1985a) . Three weeks after tumour cell injection, mice were killed, the lungs removed and the number of colonies per lung were counted with the aid of a dissecting microscope.
Flow cytometric determination of DNA content The tumours (5-10mm diameter) were removed, washed in 0.9% NaCl and minced with scissors to remove the necrotic part from the vegetal part which was used for DNA analysis. Cells were then harvested with trypsin-EDTA, washed in PBS and resuspended in a solution of 0. 1% sodium citrate containing 50 jug ml -I propidium iodide (Calbiochem-Behring Corp., La Jolla, CA, USA), 50 U ml-I RNAse A (Sigma, St. Louis, MO, USA) and 0.05% triton X-100 (Calbiochem-Behring Corp.). Mouse thymocytes used as a reference for the diploid value were processed in the same way. Flow cytometric measurements were performed with a microscope-based flow cytofluorimeter (Leitz, Wetzlar, West Germany), equipped with a 1OOWHg lamp as the source of excitation light. Excitation and emission wavelengths were selected by BG38 and BG12 excitation filters, a 580 nm chromatic beam splitter and a 610nm barrier filter. Fluorescence intensity, proportional to DNA content, was recorded by a multichannel analyzer (Spectroscope Modular 8000, Laben, Milan, Italy) and displayed as fluorescence histograms.
Pharmokinetics studies B6D2F1 mice with s.c. implanted cells were treated i.v. with DX 6.6 mg kg-1 when the tumours were palpable (5-10 mm diameter). Three animals per point were killed with ether at different times after treatment. Tumours were removed, rinsed in cold saline and stored at -70°C until drug analysis. DX was assayed from the tumours as already reported . Briefly, tumour homogenates were deproteinized by CH3CN-phosphate buffer and drug released from DNA by AgNO3 and analyzed by high performance liquid chromatography (HPLC) into a C18 reverse phase column (Perkin Elmer HS-5) with CH3CN: 0.01 M KH2PO4 pH 3.8 (34:66) as mobile phase. Detection was by fluorometry on a Perkin Elmer MPF44A spectrofluorometer at 570 nm excitation and 590 nm emission wavelengths.
Results

Dx-sensitivity of B16 melanoma lines
The activity of DX administered to mice transplanted s.c. with 106 cells of the original B16 melanoma and of the in vitro obtained lines was tested in parallel in several experiments in order to have a 'head-to-head' comparison. DX was administered i.v. at a dose of 6.6mg kg-1 starting from day 1 after tumour implant once a week for 3 weeks. This dose was chosen as the maximal tolerated dose with this schedule of treatment on non tumour-bearing B6D2F1 mice, and as the optimal therapeutic dose against B16 melanoma from a dose-response study (data not shown).
The results are reported in Table I ; only one experiment was performed with the B16VR line. Figure 2 together with the fluorescence distribution of mouse thymocytes (b) measured for reference to the diploid value.
Cells from the parental B16 melanoma show a bimodal fluorescence distribution where the first peak is similar to the G1 diploid value of thymocytes, while the second peak has the position of cells in G2 + M phase. B16V cells show a pattern similar to B16 cells while B16VDXR cells, as found in vitro (Supino et al., 1986) , show besides a first and a second peak similar to those of sensitive cells, a third peak shifted towards higher values (hypertetraploid).
In order to better characterize the in vivo behaviour of the four tumour lines, we also tested their colonization capacity by injecting different numbers of tumour cells i.v. and killing the animals three weeks later (Table III) lines became very quickly sensitive to DX: DX treatment significantly increased the tumour growth delay and the survival time of animals bearing the fifth transplants of both lines. Among the checked parameters of growth of the two lines, the latency of the tumour varied in the serial transplants in vivo and in particular it became shorter and similar to that of the DX-sensitive line with the increase in the number of transplants.
To check the outcome of DX chemotherapy in mice bearing both sensitive and resistant tumours and how resistant and sensitive cells in the same tumours influence the growth and the sensitivity of the whole tumours, mice were transplanted s.c. either with B16V cells in one flank and B16VDXR on the other flank or with 50% B16V cells and 50% B16VDXR cells in the same flank and treated with DX (Table VI) . In animals bearing separate tumours, each tumour behaved as if it was in separate animals i.e. the resistant tumour had a longer latency, compared to the sensitive one, and, differently from the sensitive one, its growth was not delayed by DX. As a whole it should be noted that DX treatment caused a significant increase of survival time with a consequent increase in metastasis incidence. In mice bearing tumours consisting of 50% sensitive and 50% resistant cells, the latency was similar to that of the sensitive line and this may be due to the fact that the growth of B16V cells, which have shorter latency, masks the latency of B16VDXR cells. In animals treated with DX, the growth of the tumour was delayed 5 days and the survival time was significantly longer compared to non-treated animals.
Therefore, these results suggest that DX-resistant cells do not influence the sensitivity of sensitive cells when present in two separate tumours or in similar percentages in the same tumour. As reported for other murine tumours (Schabel et al., 1983) , no cross-resistance was found for this The main biological properties that characterize the B16VDXR line in vivo compared to the parent line B16V are the longer latency period with consequent longer survival time and the lower colonization capacity, all features which go along with lower malignancy as reported for other drugresistant tumours (Biedler et al., 1983) . The longer latency of the B16VDXR line correlates with the in vitro longer doubling time (25 vs. 15h) (Supino et al., 1986 ) and this might be responsible for the different sensitivity to both DX and cis-DDP. In fact it has been reported that while rapidly growing tumours are more sensitive to DX than slowly growing tumours, the opposite is true for cis-DDP (Mattern et al., 1981) . The only slight differences found in the growth rates of the two tumour lines after they had become palpable is probably due to the very short doubling times of the two lines, and to the short experimental range time of tumour measurements. Extrapolation of the experimental data by Gompertz analysis is in progress.
The fact that B16VDXR showed after in vivo growth the same higher DNA content compared to the sensitive line B16V found in vitro (Supino et al., 1986) , indicates that no cell selection occurred during in vivo growth. Similarly no selection seems to have occurred in the sensitive line B16V obtained by growing the parental B16 melanoma in vitro. Karyotype analyses of the two lines are in progress in order to better understand if this modification is directly related to the drug-resistant phenotype since double minute chromosomes and homogenously staining regions have been found in different multidrug resistant cell lines and have been associated with gene amplification (Riordan & Ling, 1985) . As far as the DNA content in resistant lines compared to the sensitive ones is concerned, increase (Parsons & Morrison, 1978) or decrease (McMillan et al., 1985) in chromosome number and similar DNA content (D'Incalci et al., 1983) have been reported.
The finding that B16V and B16VDXR lines have similar spontaneous metastatic behaviour but different colonization capability extends similar observations of lack of coincidence of the two properties as reported for B16 melanoma (Stackpole, 1981) and other murine tumours (Price et al., 1984) . The lower colonization potential of the resistant line is directly related to the cloning efficiency which has been found to be 10 times lower for the resistant line (Supino et al., 1986) and confirm similar findings on B16 melanoma subclones (Stackpole et al., 1985b) . Such a correlation does not exist between the cloning efficiency and the tumourigenicity of these two lines as already reported for B16 melanoma cells in culture (Kreider & Schomayer, 1975 (Biedler et al., 1975; Biedler et al., 1983) Nowak et al., 1973) . In fact, it has been reported that treatment with anticancer drugs may lead to induction of new antigens on tumour cells (Nicolin et al., 1972) . The analysis of the relationship between the degree of resistance in vitro and the sensitivity to DX treatment in vivo, show that the B16VDXR line retained significant responsiveness in vivo in spite of a RI value of 69 and this argues about the relationship between in vitro and in vivo resistance results. From the results obtained in our study this discrepancy might be explained by the latency differences between sensitive and resistant cells with consequent in vivo predominance of sensitive cells, with shorter latency, probably still present in the resistant line at that particular RI. This possibility is supported by the fact that if resistant cells were inoculated together with similar percentages of sensitive cells, the resultant tumour behaved as if it was sensitive both in terms of latency and sensitivity.
The loss also of the resistant phenotype during few in vivo transplants might be due to latency differences between sensitive and resistant cells and to the procedure used for tumour propagation since each transplant has been performed few days after the tumours had become palpable, i.e. when most likely sensitive cells with shorter latency were replicating.
Our results on DX pharmacokinetics on the resistant line confirm the data obtained in vitro on several rodent and human tumour cell lines (Giavazzi et al., 1983; Dan0, 1983; Inaba et al., 1979; Howell et al., 1984; Rogan et al., 1984) in which the induction of DX-resistance is associated with decreased DX retention. The lack of activity of DX against the resistant line even if administered more frequently, suggests that decreased drug retention is probably only one component of resistance. In fact, B16VDXR cells have also shown when incubated with DX in vitro, a different drug intracellular distribution with lower nucleus/ cytoplasm ratio compared to the sensitive cells (Supino et al., 1986 ).
In conclusion, our results obtained with this cell line, which when first transplanted in vivo shows resistance to DX treatment, indicate this model to be suitable for in vivo studies of the mechanisms of resistance to DX and for selecting noncross-resistant drugs and drugs able to circumvent DX-resistance.
